(From Asia Pulse)
(Full text of statement. Contact details below.)
PRINCETON, N.J., March 23 /PRNewswire-AsiaNet/ --
BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Osaka, Nagoya, Fukuoka, Sapporo: 4151), its parent company, the exclusive worldwide rights, except Asia, to develop and commercialize anti IL-5 receptor antibody, a potential new asthma treatment.
Under the terms of the agreement, BioWa expects to develop and commercialize anti IL-5 receptor antibody, which is currently in late pre- clinical development, in the US and Europe. In return, Kyowa Hakko Kogyo Co. has an option to develop and commercialize the product in Asia and will be responsible for all development activities and costs. Under the terms of the agreement, BioWa retains all rights to anti IL-5 receptor antibody in non-Asia countries. Each …